BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small ce…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-2.22 | $-1.95 | $-0.33 |
| Estimado | $0.76 | $-2.08 | $-1.92 | $-0.25 |
| Sorpresa | — | -6.7% | -1.6% | -32.0% |
| Métrica | BNTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 77.6% | 57.4% | +20.3% |
| Operating Margin | -49.0% | -34.4% | -14.6% |
| Net Margin | -39.6% | -32.5% | -7.1% |
| FCF Margin | 9.8% | -12.6% | +22.4% |
| ROE | -5.9% | -39.2% | +33.3% |
| ROA | -5.2% | -30.9% | +25.8% |
| Current Ratio | 7.54 | 2.73 | +4.81 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -5.2% | — |
| ✓Flujo de caja operativo positivo | €456M | €208M |
| ✗Rentabilidad sobre activos al alza | -5.2% | -3.0% |
| ✓Caja operativa/activos supera al ROA | 2.1% | ROA -5.2% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 7.54 | 7.45 |
| ✗Sin aumentar el nº de acciones | 242M | 240M |
| ✗Margen bruto al alza | 77.6% | 80.3% |
| ✓Rotación de activos al alza | 0.13 | 0.12 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | 9.8% |
| ✗ROCE > 10 % | -7.1% |
| ✗Ventas > 5 %/año (3 años) | -45.1% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 79.4% |
Riesgo de quiebra (Altman Z 6.1): zona segura
BioNTech SE cotiza a 87.71 USD y tiene una capitalización bursátil de $22.0B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud